Skip to content
Open in App
Actinium Pharmaceuticals logo

Actinium Pharmaceuticals

web2

Actinium Pharmaceuticals develops targeted radiotherapies designed to deliver radiation to canc...

Symbol ยท ATNM
Company profile

About

Actinium Pharmaceuticals develops targeted radiotherapies designed to deliver radiation to cancer cells, with research and clinical programs focused on difficult-to-treat malignancies including relapsed cancers. Its pipeline includes Actimab-A for acute myeloid leukemia, ATNM-400, a HER3-targeted radiotherapy candidate for prostate cancer, and Iomab-ACT, a conditioning candidate being studied for cell and gene therapies. The pipeline also includes Iomab-B, intended for use before bone-marrow transplantation in patients with relapsed or refractory acute myeloid leukemia, and the company has sought a potential US partner for that program. Its operating focus is research, discovery, and clinical development rather than marketing an established portfolio of medicines.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNYSEPrimary symbol: ATNM
Expert coverage

Actinium Pharmaceuticals profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment